- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01680185
Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation (SAPT-NODAT)
Treat-To-Target Trial of Continuous Subcutaneous, Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation (SAPT-NODAT)
Study Overview
Status
Conditions
Detailed Description
Introduction: New-onset diabetes after transplantation (NODAT) is strongly associated with postoperative hyperglycemia, and reduced patient as well as graft survival. In our recent proof-of-concept clinical trial (TIP), we have shown that immediate post-transplant basal insulin therapy decreases hyperglycemia and reduces the prevalence of NODAT by improving pancreatic β-cell function. In consequence, a collaborative multicenter study on NODAT prevention using basal insulin has been approved by the National Institutes of Health (NIH), and will start recruiting 380 patients at 6 international transplant centers, including the Medical University of Vienna and the University of Michigan in 2012. In addition to the NIH-sponsored trial, the Vienna SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump in combination with a glucose sensor (SAPT), (i) improves glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers further β-cell protection, in comparison to the standard of care control group, and the basal insulin treatment group.
Methods: Combining the NIH-sponsored basal insulin study and the SAPT-NODAT study will yield three study arms, with 28 patients in each arm, namely: [1] the control arm, treated by standard-of-care; [2] the basal insulin arm, treated predominantly with intermediate acting NPH insulin (human insulin isophane, Humulin N, Eli Lilly); [3] the SAPT arm, treated with short acting insulin (Insulin lispro, Humalog, Eli Lilly), applied continuously by SAPT technology. Adult patients with absence of diabetes will be randomized prior to renal transplantation and stratified by deceased donor or living donor, if they are capable of understanding the study and are willing to give informed written consent for all three study arms. Patients will receive standard triple immunosuppressive medications (twice-daily tacrolimus, mycophenolate mofetil or mycophenolic sodium and steroids) with predefined tacrolimus targets and steroid doses. The algorithm for insulin administration is designed to account for the prominent evening peak of hyperglycemia observed in our previous TIP-study. The primary endpoint is HbA1c (in rel.%), at 3 months, and superiority will be assumed if a statistically significant difference between the SAPT-treatment group versus the standard-of-care control group can be determined, by two-sided Student's t-test. Secondary endpoints will be compared between all three groups and will include hypoglycemic events, glycemic variability, 2h glucose ≥200 mg/dL (by oral glucose tolerance test [OGTT] to determine prevalence of diabetes, prediabetes and normal glucose tolerance), beta cell function and insulin sensitivity derived from OGTT, serum creatinine, quality of life measures, patient and graft survival. All secondary endpoint comparisons relying on OGTTs will be made at 6, 12 and 24 months after kidney transplantation, respectively. The result of the 6-months OGTT will be blinded to patients and investigators to prevent subsequent treatment bias.
Discussion: Basal insulin treatment in our previous proof-of-concept study could not prevent a high number of transplant patients exhibiting overt prediabetes (impaired glucose tolerance) at 3, 6 and 12 months, probably on the basis that hyperglycemia was improved, but far from being aggressively treated in patients receiving basal insulin. Prediabetes however is an independent predictor of all-cause mortality in patients after renal transplantation, and therefore not only a harbinger of overt diabetes mellitus but rather a high-risk condition per se. The use of HbA1c as primary endpoint at three months is debatable, but necessary to determine whether SAPT technology may lead to a clinically meaningful improvement of overall glucose control. Specifically, in our previous study (TIP), we observed an intra-individual rise in HbA1c (0.5±0.7 rel.%) from baseline to 3 months, despite basal insulin treatment. If the intra-individual rise in the SAPT arm will remain below that value, SAPT technology could be considered to be a clinically meaningful improvement. The SAPT-NODAT study, besides holding promise to further improve glycemic control, thereby reducing diabetes, prediabetes and possibly cardiovascular events after transplantation, may ensure that the present team of investigators continues to take the lead in post-transplant insulin administration, which is emerging as a central focus in NODAT-prevention and may soon reach broader clinical application.
(Study approval: EK-Nr. 10/2012)
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients with end stage renal disease undergoing kidney transplantation with a deceased or living donor kidney.
- Absence of diabetes prior to kidney transplantation, defined according to American Diabetes Association guideline (not on oral hypoglycemic agents or insulin with fasting glucose <126 mg/dL).
- Receiving standard triple immunosuppressive medications that include tacrolimus, mycophenolate mofetil or mycophenolic sodium and steroids.
- Capable of understanding the study and willing to give informed written consent for study participation.
Exclusion Criteria:
- Patients with a diagnosis of diabetes mellitus prior to kidney transplantation, or receiving anti-diabetic medications, or having pre-transplant fasting glucose level equal or greater than 126 mg/dL on two occasions at least three days apart.
- Patients receiving an organ transplant other than kidney.
- Patients receiving an unlicensed drug or therapy within one month prior to study entry.
- Patients with history of hypersensitivity to injectable insulin.
- Patients with documented HIV infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sensor-augmented Insulin Pump
Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
|
all covered above
|
Active Comparator: Basal insulin
NPH insulin titration regimen, as specified in the IPT-NODAT study
|
all covered above
|
Active Comparator: Standard of care
Patients assigned in this arm will receive standard of care following their kidney transplantation
|
all covered above
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycosylated hemoglobin (HbA1c)
Time Frame: 3 months after transplantation
|
HbA1c levels, in relative %, at 3 months.
Superiority will be assumed if a statistically significant difference between the SAPT-treatment group versus the control group (from the ITP-NODAT study) can be determined.
|
3 months after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycosylated hemoglobin (HbA1c)
Time Frame: 3, 6, 12, 24 months after transplantation
|
HbA1c, in relative %, at 3, 6, 12 and 24 months post-transplantation; The baseline measurement will also be subtracted from the 3-, 6-, 12-, and 24-months measurement (i.e.
"3-months, 6-months, 12-months, and 24-months HbA1c minus baseline HbA1c").
For the determination of the intra-individual rise in HbA1c, the previously observed rise of 0.5±0.7 % (mean ± standard deviation) from baseline to 3 months in the TIP-study basal insulin treatment group will be judged to be clinically not meaningful, hence if the intra-individual rise in the SAPT-treatment group remains below that value, the rise in HbA1c will be considered to be not meaningful, clinically.
|
3, 6, 12, 24 months after transplantation
|
Oral glucose tolerance test (OGTT)-derived 2 hour-glucose
Time Frame: 6, 12, 24 months after transplantation
|
2h glucose ≥200 mg/dL, as by OGTT at 6, 12 and 24 months after transplantation (in comparison to the simultaneously monitored control group of the ITP-NODAT study [=arm B; control])
|
6, 12, 24 months after transplantation
|
Fasting glucose
Time Frame: 6, 12, 24 months after transplantation
|
Fasting glucose and 2h glucose at 6, 12 and 24 months after transplantation.
|
6, 12, 24 months after transplantation
|
Beta cell function
Time Frame: 6, 12, 24 months after transplantation
|
Insulinogenic index during an OGTT at 6, 12 and 24 months after kidney transplantation
|
6, 12, 24 months after transplantation
|
Insulin sensitivity
Time Frame: 6, 12, 24 months after transplantation
|
Oral glucose insulin sensitivity (OGIS) index at 6, 12 and 24 months after kidney transplantation
|
6, 12, 24 months after transplantation
|
Daily glucose measurements
Time Frame: Daily glucose measurements will be obtained during the hopital stay and while patients are injecting insulin, during an expected average of 3 months.
|
Daily glycemia profile, through evaluation of all available glucose measurements
|
Daily glucose measurements will be obtained during the hopital stay and while patients are injecting insulin, during an expected average of 3 months.
|
Serum creatinine
Time Frame: 6, 12 and 24 months after transplantation
|
Serum creatinine at 6, 12 and 24 months after kidney transplantation
|
6, 12 and 24 months after transplantation
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAPT-NODAT_9march2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
University Hospital, Gentofte, CopenhagenCompletedPancreatectomy; HyperglycemiaDenmark
-
Egas Moniz - Cooperativa de Ensino Superior, CRLCompletedHyperglycemia, PostprandialPortugal
-
National University, SingaporeNational University Health System, SingaporeCompletedPostprandial HyperglycemiaSingapore
-
Coordinación de Investigación en Salud, MexicoUnknownStress HyperglycemiaMexico
-
University of Eastern FinlandCompletedPostprandial HyperglycemiaFinland
-
University of LeedsCompletedHyperglycemia, PostprandialUnited Kingdom
Clinical Trials on Insulin lispro, Humalog (Eli Lilly) in insulin pump
-
Medical University of ViennaMedical University of Graz; Charite University, Berlin, Germany; Hospital del...Completed
-
Kaplan Medical CenterUnknown
-
Diasome PharmaceuticalsIntegriumCompletedType 1 Diabetes MellitusUnited States
-
Sun Yat-sen UniversityEli Lilly and Company; Ministry of Health, China; Amylin Pharmaceuticals, LLC.CompletedDiabetes Mellitus, Type 2 | Newly DiagnosedChina
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Taiwan, China, Korea, Republic of
-
Eli Lilly and CompanyCompleted
-
Hadassah Medical OrganizationUnknownCystic Fibrosis | Impaired Glucose Tolerance | Pulmonary ExacerbationIsrael
-
Diasome PharmaceuticalsIntegriumCompletedType1 Diabetes MellitusUnited States
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 1United States
-
Eli Lilly and CompanyCompleted